Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.00    4.50 (0.90%)
Bid:
505.00
Ask:
505.50
Spread: 0.50 (0.099%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Integration update and pre-close statement

15 Apr 2025 07:00

RNS Number : 9797E
Tate & Lyle PLC
15 April 2025
 

15 April 2025 - Tate & Lyle PLC: Integration update and Pre-close statement

 

Integration of CP Kelco on-track, Tate & Lyle operating as one combined business

 

Tate & Lyle issues the following update on the CP Kelco integration and a pre-close statement for the year ended 31 March 2025 ahead of the announcement of full-year results on 22 May 2025.

 

Headlines

· Integration on-track, confident in synergy delivery, operating as one combined business from 1 April 2025

· Tate & Lyle performed as expected in Q4 with 2025 financial year results to be in line with guidance

· CP Kelco trading well and will deliver over 90bps increase in EBITDA margin1,2 in year to 31 March 2025

· Strong free cash flow with Net debt to EBITDA expected to be 2.2x at 31 March 2025

· Capital Markets event for investors and analysts to be held in the first week of July 2025.

 

Nick Hampton, Chief Executive said

"Notwithstanding the uncertain macroeconomic environment, we are confident in the medium-term growth potential of the business we have created and are focused on delivering the benefits of the combination with CP Kelco and accelerating topline growth.  Our confidence in the growth opportunity ahead has been strengthened by the positive engagement we are seeing from customers in both our expanded portfolio and capabilities.

 

In line with our normal practice, we will provide an update on the business when we announce our full-year results on 22 May 2025."

 

Trading update

Tate & Lyle performed as expected in Q4 and for the year ended 31 March 2025 will be in line with guidance. Excluding CP Kelco and in constant currency, we expect revenue will be 5% lower and EBITDA will be 4% higher.

 

CP Kelco continues to trade well and will deliver an increase in EBITDA margin1,2 of over 90bps in the year ended 31 March 2025, ahead of our acquisition plan. This progress further reinforces our confidence in its phased margin recovery.

 

CP Kelco integration

The integration is progressing well and as planned, with Tate & Lyle and CP Kelco operating as one combined business from 1 April 2025. We continue to focus on three key areas to deliver the significant value we see from the combination:

· People: The new organisation and leadership team are now established and, from 1 April 2025, we have been operating under a new regional framework ‒ Americas; Asia Pacific; Europe, Middle East and Africa.

· Performance: We are confident in delivering the targeted run-rate cost synergies of US$50 million by the end of the 2027 financial year, and for more than 50% of these to be delivered by the end of the 2026 financial year. 

· Customers: The transition to the combined business has been executed well, and we are seeing positive engagement from customers to both our expanded portfolio and capabilities, reinforcing our confidence in the delivery of the identified revenue synergies of up to 10% of CP Kelco's revenue over the medium-term.

Balance sheet

Cash generation remains strong with cash conversion3 for the 2025 financial year exceeding 75%, in line with our long-term ambition. Net debt to EBITDA at 31 March 2025 is expected to be 2.2 times, better than anticipated when we acquired CP Kelco reflecting disciplined cash management and the momentum in CP Kelco's margin recovery.

 

Capital Markets event

We will be hosting a Capital Markets event for investors and analysts on Tuesday 1 July 2025 in London.This will be followed by a site visit to our pectin facility and labs in Lille Skensved, near Copenhagen on Thursday 3 July 2025. To register your interest for either, or both, of these days, please contact Lucy Huang at lucy.huang@tateandlyle.com.

 

---------------------------------------------------------------------------------

Notes

1. Adjusted EBITDA margin is a non-GAAP measure, see definition of non-GAAP measures on page 147 of the Tate & Lyle annual report for the year ended 31 March 2024.

2. Change in adjusted EBITDA margin is in constant currency and compares to the restated adjusted EBITDA for the year ended 31 March 2024 of £100 million. The restatement reflects the inclusion of incremental costs of operating CP Kelco as a standalone business. The previously published CP Kelco adjusted EBITDA for that year was £106 million which excluded all recharges of operating costs from CP Kelco's previous owner.

3. Cash conversion is free cash flow before capital expenditure divided by adjusted EBITDA. 

 

END

For more information contact Tate & Lyle PLC:

 

Christopher Marsh, VP, Investor Relations

Mobile: +44 (0)7796 192 688

 

Nick Hasell (FTI Consulting), Media Relations

Mobile: +44 (0)7825 523 383

 

About Tate & Lyle:

Supported by our 165-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients and solutions every day.

 

Through our leading expertise in sweetening, mouthfeel and fortification, we develop ingredients and solutions which reduce sugar, calories and fat, add fibre and protein, and provide texture and stability to food and drink in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

 

Tate & Lyle recently acquired CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients to create a leader in mouthfeel, significantly enhancing our solutions capabilities. Following this combination, we now have more than 5,000 employees working in around 75 locations in 38 countries, serving customers in more than 120 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives through the Science of Food. By living our purpose, we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. For the year ended 31 March 2024, and on a pro forma basis which assumes for illustrative purposes that the combination with CP Kelco took place on 1 April 2023, revenue for the enlarged Tate & Lyle Group would have been £2.25 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on X, Linkedin, Facebook or YouTube

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUACCUPAGQC
Date   Source Headline
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company
10th Aug 20234:00 pmRNSHolding(s) in Company
7th Aug 202312:15 pmRNSDirector/PDMR Shareholding
3rd Aug 20233:45 pmRNSDirector/PDMR Shareholding
2nd Aug 202311:30 amRNSHolding(s) in Company
1st Aug 202311:15 amRNSTotal Voting Rights
28th Jul 202312:00 pmRNSDirector/PDMR Shareholding
27th Jul 20231:15 pmRNSResult of AGM
27th Jul 20239:30 amRNSHolding(s) in Company
26th Jul 202311:30 amRNSHolding(s) in Company
25th Jul 202311:30 amRNSHolding(s) in Company
24th Jul 202312:30 pmRNSHolding(s) in Company
18th Jul 202312:30 pmRNSHolding(s) in Company
4th Jul 20233:00 pmRNSDirector/PDMR Shareholding
3rd Jul 20232:10 pmRNSBlock listing Interim Review
3rd Jul 20232:00 pmRNSTotal Voting Rights
3rd Jul 20237:02 amRNSDirectorate Change
29th Jun 20233:30 pmRNSHolding(s) in Company
28th Jun 20232:00 pmRNSHolding(s) in Company
7th Jun 20232:30 pmRNSDirector/PDMR Shareholding
6th Jun 202312:30 pmRNSAnnual Financial Report and Notice of AGM 2023
1st Jun 202312:00 pmRNSTotal Voting Rights
25th May 20237:00 amRNSFinal Results
18th May 20239:30 amRNSDirector Declaration
2nd May 20232:30 pmRNSTotal Voting Rights
4th Apr 202311:00 amRNSOperating Segment Restatement
3rd Apr 20234:15 pmRNSTotal Voting Rights
8th Mar 20232:30 pmRNSDirector/PDMR Shareholding
8th Feb 20237:00 amRNSCapital Markets Event
26th Jan 20237:00 amRNSTrading Statement
6th Jan 20232:00 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:17 pmRNSBlock listing Interim Review
8th Dec 20221:00 pmRNSDirector/PDMR Shareholding
30th Nov 20222:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.